Clinical trials assess G8 tool's risk assessment and its impact on progression-free survival in elderly glioblastoma patients, suggesting it may guide treatment decisions.
Key Points
This research aims to evaluate the prognostic significance of the G8 geriatric screening tool in elderly glioblastoma patients.
Analysis of data from 83 patients aged 70 or older enrolled in the 1608 and 1709 EORTC trials.
Classification of patients into G8 low (≤14) and high (15-17) groups based on G8 scores.
Assessment of clinical outcomes including KPS, treatment delivery, and survival rates.
Patients in the G8 high group showed longer progression-free survival (HR = 0.37) and overall survival (HR = 0.40).
Higher toxicity was noted in the G8 low group compared to the high group.
Adjusted odds ratios indicated better treatment delivery in those with higher G8 scores.